Since TNBC is highly aggressive, has limited therapeutic options, and is chemoresistant, further investigation was focused on exploring PON2’s involvement in the molecular mechanisms underlying cell proliferation and sensitivity to drug treatment affecting this tumor form. The gene discussed is PON2; the disease is neoplasm.